论文部分内容阅读
根据目前临床使用的铂类抗癌药物的缺点和不足,作者报道了一种结构新颖的铂类配合物的合成方法,通过元素分析、质谱、红外、核磁共振氢谱等对合成物进行了结构表征,确认合成物为目标化合物。采用SRB比色法,测定的化合物对A549癌细胞及KB癌细胞的半数抑制浓度(IC50)分别为13.4mg/L和20.0mg/L。
According to the shortcomings and deficiencies of platinum anticancer drugs currently used clinically, the authors reported a novel method for the synthesis of platinum complexes. The structures of the complexes were characterized by elemental analysis, mass spectrometry, infrared spectroscopy and nuclear magnetic resonance Characterization confirmed the compound as the target compound. The half-maximal inhibitory concentrations (IC50) of the compounds tested on the A549 cancer cells and the KB cancer cells by SRB colorimetry were 13.4 mg / L and 20.0 mg / L, respectively.